In this interview with The Dales Report, InMed CEO Eric A. Adams talks about how the scalability of synthesized rare cannabinoids will make them more affordable.
Read the article and watch the full video at The Dales Report.
What quality controls should be put in place to ensure consistency and purity of cannabinoids for CPG products?
Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, answers these questions: What is the minimum GMP standard that consumers should expect? What quality controls should
August 18, 2023
